JP2022545530A5 - - Google Patents

Info

Publication number
JP2022545530A5
JP2022545530A5 JP2022513077A JP2022513077A JP2022545530A5 JP 2022545530 A5 JP2022545530 A5 JP 2022545530A5 JP 2022513077 A JP2022513077 A JP 2022513077A JP 2022513077 A JP2022513077 A JP 2022513077A JP 2022545530 A5 JP2022545530 A5 JP 2022545530A5
Authority
JP
Japan
Prior art keywords
seq
vaccine
epicensus
amino acid
hbv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022513077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545530A (ja
JP7635208B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048411 external-priority patent/WO2021045969A1/en
Publication of JP2022545530A publication Critical patent/JP2022545530A/ja
Publication of JP2022545530A5 publication Critical patent/JP2022545530A5/ja
Application granted granted Critical
Publication of JP7635208B2 publication Critical patent/JP7635208B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022513077A 2019-08-29 2020-08-28 Ｂ型肝炎ウイルスワクチン Active JP7635208B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962893546P 2019-08-29 2019-08-29
US62/893,546 2019-08-29
US201962941125P 2019-11-27 2019-11-27
US62/941,125 2019-11-27
PCT/US2020/048411 WO2021045969A1 (en) 2019-08-29 2020-08-28 Hepatitis b virus vaccines

Publications (3)

Publication Number Publication Date
JP2022545530A JP2022545530A (ja) 2022-10-27
JP2022545530A5 true JP2022545530A5 (enExample) 2023-08-22
JP7635208B2 JP7635208B2 (ja) 2025-02-25

Family

ID=74096044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513077A Active JP7635208B2 (ja) 2019-08-29 2020-08-28 Ｂ型肝炎ウイルスワクチン

Country Status (12)

Country Link
US (1) US12485168B2 (enExample)
EP (1) EP4021923A1 (enExample)
JP (1) JP7635208B2 (enExample)
KR (1) KR20220090497A (enExample)
CN (1) CN114729010B (enExample)
AU (1) AU2020342385A1 (enExample)
BR (1) BR112022003474A2 (enExample)
CA (1) CA3149415A1 (enExample)
IL (1) IL290924A (enExample)
MX (1) MX2022002270A (enExample)
PH (1) PH12022550490A1 (enExample)
WO (1) WO2021045969A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4458975A3 (en) 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300213A1 (en) 1987-06-22 1989-01-25 Hexal-Pharma Gentechnik GmbH & Co. KG Hepatitis a viral peptide particle immunogens
DE19904800C1 (de) 1999-02-05 2001-02-08 Eberhard Hildt Partikel zur Gentherapie
JP2003511075A (ja) 1999-10-08 2003-03-25 セルテック ファーマ ユアロップ リミテッド 免疫原の設計
EP1294893B1 (en) 2000-06-22 2006-03-15 UCB Pharma Limited Modification of hepatitis b core antigen
WO2002094866A1 (en) * 2001-05-25 2002-11-28 Dobeel Corp Pre-s protein of hepatitis b virus (hbv) as an adjuvant and a component of hbv vaccine
WO2003083094A1 (en) 2002-03-29 2003-10-09 Innogenetics N.V. Hbv drug resistance drug resistance detection methods
JP2007509614A (ja) * 2003-10-21 2007-04-19 メルボルン ヘルス Ｈｂｖ変種の検出および適用
EP2497831B1 (en) 2004-05-25 2014-07-16 Oregon Health and Science University TB vaccination using HCMV-based vaccine vectors
WO2007140522A1 (en) 2006-06-06 2007-12-13 Melbourne Health Detection and use of antiviral resistance mutations
US20080171062A1 (en) * 2006-08-16 2008-07-17 Monica Sala-Schaeffer Recombinant HBsAg virus-like particles containing polyepitopes of interest, their production and use
BR112012002628B1 (pt) 2009-08-07 2021-09-08 Transgene Sa Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP3333265B1 (en) 2010-05-14 2020-02-05 Oregon Health & Science University Recombinant hcmv and rhcmv vectors encoding a heterologous antigen isolated from hepatitis b virus and uses thereof
JP5745102B2 (ja) 2011-02-12 2015-07-08 グローブイミューン，インコーポレイテッド 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
KR101418836B1 (ko) * 2012-04-05 2014-08-13 서울대학교산학협력단 간질환 진단용 마커 및 이의 용도
US8852745B2 (en) 2012-10-12 2014-10-07 Hoya Corporation Optical glass, press-molding glass material, optical element and method of manufacturing the same, and bonded optical element
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
SI2964769T1 (sl) 2013-03-05 2018-12-31 Oregon Health & Sccience University Citomegalovirusni vektorji, ki omogočajo krmiljenje ciljanja T-celic
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
CN114317611A (zh) 2015-02-10 2022-04-12 俄勒冈健康与科学大学 可用于产生非典型cd8+t细胞应答的方法和组合物
DK3402888T3 (da) 2016-01-12 2020-11-30 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Middel og fremgangsmåder til behandling af hbv
CN110036112B (zh) * 2016-10-18 2024-05-10 俄勒冈健康与科学大学 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体
GB201705765D0 (en) 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd HBV vaccine
US12599658B2 (en) * 2019-06-07 2026-04-14 Oregon Health & Science University Hepatitis B virus-specific T cell responses

Similar Documents

Publication Publication Date Title
Milich et al. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site
Pumpens et al. HBV core particles as a carrier for B cell/T cell epitopes
KR100208129B1 (ko) B형 간염 백신
Kamili et al. Efficacy of hepatitis B vaccine against antiviral drug‐resistant hepatitis B virus mutants in the chimpanzee model
JP2021182922A5 (enExample)
Saito et al. Plasmid DNA-based immunization for hepatitis C virus structural proteins: immune responses in mice
Dietzschold et al. New approaches to the prevention and eradication of rabies
JP2017515508A5 (enExample)
Noordeen Hepatitis B virus infection: An insight into infection outcomes and recent treatment options
Keese et al. Nucleotide sequence of the genome of an Australian isolate of turnip yellow mosaic tymovirus
WO2002013855A2 (en) Vaccines containing ribavirin and methods of use thereof
JP2003055265A (ja) 肝炎療剤
EP3342866A1 (en) Polypeptide carrier for presenting target polypeptide and uses thereof
Chima et al. Molecular epidemiology of human polyomavirus JC in the Biaka Pygmies and Bantu of Central Africa
JP2020515241A (ja) 標的ポリペプチドを提示するためのポリペプチド担体及びその使用
CN1733798B (zh) 乙型肝炎病毒表面l蛋白相关肽
JP7635208B2 (ja) Ｂ型肝炎ウイルスワクチン
JP2004121266A (ja) コンビナトリアルポリペプチド抗原
CN115197969B (zh) 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用
CN102675430B (zh) 乙型肝炎病毒表面l蛋白相关肽
EP3432923B1 (en) Hcv vaccines
Cheong et al. Modulation of the immunogenicity of virus-like particles composed of mutant hepatitis B virus envelope subunits
Björnsdottir et al. Changing prevalence of hepatitis B virus genotypes in Iceland
CN104130316B (zh) 乙型肝炎病毒表面l蛋白相关肽
US6280734B1 (en) Simian-human HAV having a chimeric 2C protein